Remdesivir is an important option for patients who lack the COVID-19 treatment options available to non-immunocompromised patients.
Remdesivir tied to lower death rates in COVID hospital patients with weakened immune systems
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Data suggest SARS-CoV-2 could jump from raccoon dogs to people, but species barrier may interfere
- Quick takes: Moderna’s RSV vaccine, flu-COVID combo vaccines, new polio cases
- Study: US children at times received ineffective COVID-19 treatments
- NIH announces long-COVID trials to examine treatments for sleep, exercise disruptions